When clinicians have questions like “What is retatrutide?”, they are usually asking about more than its identity as a triple-agonist peptide. They want to know what the weight-loss and cardiometabolic evidence actually shows. Retatrutide (LY3437943) activates the GIP, GLP-1, and glucagon receptors together, and a fast-growing body of trial data now spans the original Phase 2 program through the Phase 3 TRIUMPH trials, with results reported through 2026.
Studies have associated retatrutide with weight loss approaching the levels seen after bariatric surgery, along with improvements in several cardiometabolic risk factors among adults with obesity [1][2]. At Medica Depot, we cover the retatrutide literature that clinicians most often ask about, including the considerations licensed professionals weigh when deciding how to buy retatrutide for approved research applications.
This article looks at how researchers are studying retatrutide’s triple-agonist mechanism in obesity, what Phase 2 and Phase 3 trials have found so far about weight loss and cardiometabolic health, and why some researchers frame it as a major step beyond earlier GLP-1-based medications.
Key Takeaways
- Retatrutide is an investigational peptide activating GIP, GLP-1, and glucagon receptors. It is being studied in Phase 3 trials for obesity and related cardiometabolic conditions but has not been approved as a treatment.
- In the Phase 3 TRIUMPH-1 trial, participants at the 12 mg dose lost an average of 28.3% of body weight at 80 weeks under the efficacy estimand (on-treatment effect), with the treatment-regimen estimand (intent-to-treat regardless of adherence) at approximately 25.0%. A longer-term extension reported weight loss of up to 30.3%, building on the Phase 2 result of up to 24.2% at 48 weeks.
- Studies also documented consistent improvements in blood pressure, cholesterol and other lipids, glycemic control, and liver fat [1][2]. Researchers frame retatrutide’s multi-hormonal design as a potential shift in obesity pharmacotherapy, though it remains investigational, with an FDA filing not expected before 2027 [2].
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. We offer a worry-free experience in searching for the best and most popular products on the market, like retatrutide research peptides. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
What Is Retatrutide, and Why Does It Matter for Obesity Research?
At the identity level, retatrutide is a synthetic single-chain peptide built on a GIP backbone. It is linked to a fatty-acid group that extends its half-life, allowing once-weekly subcutaneous administration. Unlike semaglutide and tirzepatide, retatrutide is designed to activate three receptors (GLP-1, GIP, and glucagon) at varying potencies, with the goal of influencing appetite, glycemic regulation, and energy expenditure through a single molecule.
Developed by Eli Lilly, retatrutide has moved from early Phase 1 dose-finding studies through a completed Phase 2 program and, as of 2026, has produced topline Phase 3 results across the TRIUMPH program [1][2]. It remains investigational and has not received FDA approval. Lilly has indicated it intends to submit for regulatory review in early 2027 [2].
Fuller nomenclature and structural detail is covered elsewhere in our retatrutide coverage. Here, the focus stays on what that design does for obesity and cardiometabolic comorbidities.
How Does a Triple Agonist Change the Weight-Loss Equation?
Retatrutide’s three receptor targets are thought to contribute distinct, complementary effects to weight loss:
- GLP-1 receptor agonism reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the same pathway that underlies currently available medical weight-loss agents.
- GIP receptor agonism may strengthen incretin signaling and, when combined with GLP-1 activation, could produce greater improvements in weight and glycemic control.
- Glucagon receptor activation may raise energy expenditure and support hepatic fat oxidation, effects that GLP-1-only and dual GIP/GLP-1 medications do not provide.
Retatrutide is engineered to work through all three pathways at once, targeting several aspects of obesity biology (appetite, glycemic regulation, and energy expenditure) simultaneously. Researchers often cite this combined approach as one reason retatrutide has produced stronger trial results than earlier single- and dual-agonist medications [1].
What Does Trial Data Show for Weight Loss in Adults with Obesity?
The original efficacy signal came from a 48-week, Phase 2, randomized, placebo-controlled trial in adults with obesity or overweight plus at least one weight-related comorbidity. At the 12 mg dose, retatrutide produced a mean weight reduction of 24.2% at 48 weeks, compared with 2.1% for placebo, and the weight-loss curve had not yet plateaued at trial end [1].
Phase 3 data have since built on that signal. TRIUMPH-1, an 80-week trial enrolling more than 2,300 adults with obesity or overweight and at least one weight-related comorbidity without type 2 diabetes, reported average weight loss of 28.3% at the 12 mg dose under the efficacy estimand and approximately 25.0% under the treatment-regimen estimand. More than 45% of participants lost at least 30% of body weight, a threshold historically associated with bariatric surgery. In a 24-week extension enrolling participants with a baseline BMI of 35 or higher, average weight loss reached 30.3% at 104 weeks [2].
A related trial, TRIUMPH-4, reported 28.7% weight loss at 68 weeks in adults with obesity and knee osteoarthritis [5]. Together, this Phase 2-to-Phase 3 progression is what underlies the framing of retatrutide for obesity as a dramatically effective finding relative to earlier incretin-based agents. Phase 3 figures remain topline results pending full peer-reviewed publication, and retatrutide is an experimental molecule rather than an approved treatment [2][5].
Where Does the “Paradigm Shift” Framing Come From?
- Magnitude of Weight Loss: Phase 3 data now report averages in the high-20% range under the efficacy estimand, with a meaningful share of participants reaching surgical-level weight loss. This exceeds currently approved single GLP-1 and dual GIP/GLP-1 agents in comparable trial populations [2].
- Broadness of Effect: Beyond weight, retatrutide has improved blood pressure, lipids, glycemic control, and liver fat in the same trial populations, suggesting benefit across the metabolic syndrome cluster rather than any single risk factor [1][4][5].
- Design: As a triple-receptor agonist developed by Eli Lilly, retatrutide is often cited as an example of “systems pharmacology,” engaging multiple hormonal axes together to address obesity and its comorbidities as an interconnected problem.
Whether this translates into a genuine shift in clinical practice will depend on completion of the Phase 3 program, FDA review, and longer-term cardiovascular outcomes data still being collected [2].
Beyond Body Weight: What Cardiometabolic Markers Move in the TRIUMPH Program?
Obesity often clusters with hypertension, dyslipidemia, insulin resistance, hepatic steatosis, and visceral adiposity, all of which contribute to cardiometabolic risk. Retatrutide trials have tracked this broader panel alongside weight.
In a substudy of adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), once-weekly retatrutide produced liver-fat reductions of up to roughly 82% from baseline at 24 weeks at the 12 mg dose, with normal liver-fat levels achieved in most higher-dose participants [4].
Phase 2 data also documented improvements in systolic and diastolic blood pressure, triglycerides, LDL and non-HDL cholesterol, and glycated hemoglobin, and a meta-analysis of randomized trials confirmed statistically significant reductions in both blood pressure and lipid parameters [1][3]. Phase 3 TRIUMPH-4 data reported a 14.0 mmHg reduction in systolic blood pressure at the 12 mg dose, alongside improvements in non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein [5].
In adults with type 2 diabetes and obesity, Phase 2 data documented HbA1c reductions of up to roughly 2 percentage points at 24 and 36 weeks, with as many as 82% of participants reaching an HbA1c below 6.5% [3]. Phase 3 TRIUMPH-2 data in a similar population reported average weight loss of up to 20.8% at 80 weeks alongside continued glycemic improvement [2].
Taken together, retatrutide is being studied not only as a weight-loss agent but as a candidate multi-system intervention for the cardiometabolic comorbidities that most often accompany obesity.
What Does Current Evidence Suggest About Safety and Tolerability?
Across studies in obesity, type 2 diabetes, and osteoarthritis, retatrutide’s safety profile has generally looked similar to those of other incretin-based agents. The most common side effects were gastrointestinal (nausea, diarrhea, vomiting, constipation), usually mild to moderate and most frequent during dose escalation [1][5]. At higher doses, a small number of participants reported dysesthesia, and studies documented modest, dose-related increases in resting heart rate consistent with the wider GLP-1-based class [1][5].
Topline Phase 3 results have not surfaced major new safety concerns so far, though a full long-term profile will depend on peer-reviewed publications and outcomes data still to come [2].
Which Populations Are Being Studied Across the TRIUMPH Program?
Retatrutide has been studied in several overlapping populations. The original Phase 2 obesity trial included adults with obesity (BMI ≥30 kg/m²) and adults who were overweight (BMI ≥27 kg/m² plus at least one weight-related condition). Most participants did not have type 2 diabetes [1].
Later Phase 3 studies expanded to adults with type 2 diabetes and obesity (TRIUMPH-2), established cardiovascular disease (TRIUMPH-3), and knee osteoarthritis (TRIUMPH-4), as well as the MASLD substudy. Together, these allow investigators to examine weight loss and organ-specific effects across a range of cardiometabolic risk profiles [2][4][5]. Across the program, more than 5,800 participants have now been enrolled, with additional trials in obstructive sleep apnea and long-term cardiovascular outcomes still underway [2].
Clinicians weighing where retatrutide sits against the currently approved incretin-based agents can review comparisons like retatrutide vs. semaglutide vs. tirzepatide, which typically discuss mechanism, trial outcomes, and how the three agents are being positioned for medical weight-loss selection.
Looking to buy retatrutide online? Get in touch with our customer service representatives at Medica Depot for further guidance.
The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.
Citations
[1] Jastreboff, Ania M et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.” The New England journal of medicine vol. 389,6 (2023): 514-526. doi:10.1056/NEJMoa2301972
[2] Eli Lilly and Company. “Lilly’s Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial.” Eli Lilly Investor Relations, 21 May 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
[3] Rosenstock, Julio et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.” Lancet (London, England) vol. 402,10401 (2023): 529-544. doi:10.1016/S0140-6736(23)01053-X
[4] Sanyal, Arun J et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nature medicine vol. 30,7 (2024): 2037-2048. doi:10.1038/s41591-024-03018-2
[5] Eli Lilly and Company. “Lilly’s Triple Agonist, Retatrutide, Delivered Weight Loss of up to an Average of 71.2 Lbs Along With Substantial Relief From Osteoarthritis Pain in First Successful Phase 3 Trial.” Eli Lilly Investor Relations. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
This content was prepared and reviewed under our editorial guidelines , which govern how we source, verify, and update clinical and product information. Every claim is checked against peer-reviewed research, manufacturer documentation, or regulatory guidance before publication.
